27
Participants
Start Date
June 30, 2005
Primary Completion Date
March 31, 2007
Study Completion Date
March 31, 2011
Alemtuzumab
T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
Cyclosporine
Oral immunosuppressant
Mycophenolate mofetil
Oral immunosuppressant
Tacrolimus
Oral immunosuppressant
Liver transplant
Occurs at study entry
Immunosuppression withdrawal
Beginning no earlier than Year 1
University of Pennsylvania, Philadelphia
University of Miami School of Medicine, Miami
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
University of Wisconsin, Madison
Baylor University, Dallas
University of Colorado, Denver
University of California, San Francisco, San Francisco
University of Alberta, Edmonton
Immune Tolerance Network (ITN)
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH